Search research articles
Contact Us
Filters
Showing results (11-20 of 16) with videos related to
Page
of 2
Sort By:
You have reached the last page of results.
This site can display upto 16 results.
Dermatology (Basel, Switzerland)
|
June 9, 2005
Novel application of layered expression scanning for proteomic profiling of plucked hair follicles
June L Traicoff, Galina Baibakov, Greg Biesecker, et al.
Anticancer Research
|
January 31, 2012
The evaluation of E-Cadherin and vimentin as biomarkers of clinical outcomes among patients with non-small cell lung cancer treated with erlotinib as second- or third-line therapy
Frank Richardson, G David Young, Regina Sennello, et al.
Cancer Chemotherapy and Pharmacology
|
December 14, 2004
Incorporation of OSI-7836 into DNA of Calu-6 and H460 xenograft tumors
Frank Richardson, Chris Black, Katherine Richardson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 10, 2011
A randomized, phase II, biomarker-selected study comparing erlotinib to erlotinib intercalated with chemotherapy in first-line therapy for advanced non-small-cell lung cancer
Fred R Hirsch, Fairooz Kabbinavar, Tim Eisen, et al.
The New England Journal of Medicine
|
July 15, 2005
Erlotinib in lung cancer - molecular and clinical predictors of outcome
Ming-Sound Tsao, Akira Sakurada, Jean-Claude Cutz, et al.
Cancer Research
|
January 21, 2006
OSI-930: a novel selective inhibitor of Kit and kinase insert domain receptor tyrosine kinases with antitumor activity in mouse xenograft models
Andrew J Garton, Andrew P A Crew, Maryland Franklin, et al.
Page
of 2
Search research articles
Search
Showing results (11-20 of 16) with videos related to
Sort By:
Page
of 2
You have reached the last page of results.
This site can display upto 16 results.
Dermatology (Basel, Switzerland)
|
June 9, 2005
Novel application of layered expression scanning for proteomic profiling of plucked hair follicles
June L Traicoff, Galina Baibakov, Greg Biesecker, et al.
Anticancer Research
|
January 31, 2012
The evaluation of E-Cadherin and vimentin as biomarkers of clinical outcomes among patients with non-small cell lung cancer treated with erlotinib as second- or third-line therapy
Frank Richardson, G David Young, Regina Sennello, et al.
Cancer Chemotherapy and Pharmacology
|
December 14, 2004
Incorporation of OSI-7836 into DNA of Calu-6 and H460 xenograft tumors
Frank Richardson, Chris Black, Katherine Richardson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 10, 2011
A randomized, phase II, biomarker-selected study comparing erlotinib to erlotinib intercalated with chemotherapy in first-line therapy for advanced non-small-cell lung cancer
Fred R Hirsch, Fairooz Kabbinavar, Tim Eisen, et al.
The New England Journal of Medicine
|
July 15, 2005
Erlotinib in lung cancer - molecular and clinical predictors of outcome
Ming-Sound Tsao, Akira Sakurada, Jean-Claude Cutz, et al.
Cancer Research
|
January 21, 2006
OSI-930: a novel selective inhibitor of Kit and kinase insert domain receptor tyrosine kinases with antitumor activity in mouse xenograft models
Andrew J Garton, Andrew P A Crew, Maryland Franklin, et al.
Page
of 2